A randomized,multicentre,open-label,parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

Abstract

Injection site reactions (ISRs) are a common side effect of subcutaneous interferon beta therapy, particularly during initiation of therapy. Retrospective analysis of two clinical trials showed that patients using an autoinjector experienced fewer ISRs than patients administering interferon beta manually. This randomized, open-label trial compared the occurrence of ISRs in relapsing-remitting multiple sclerosis patients subcutaneously injecting interferon beta-1a manually or with autoinjector. In total, 1825 patients (autoinjector, 932; manual injection, 893) were included in the intention-to-treat analysis. Significantly fewer patients using the autoinjector experienced ISRs, based on physician assessment, compared with manual injection (78.7% versus 85.4%; p<0.001). There was no statistical difference on primary study endpoint: number of patients experiencing moderate to severe ISRs after 12 weeks’ therapy (25.3% versus 23.2%, P=0.449). The patient-reported proportion of any ISR during the treatment period was significantly greater for the manual injection group (71.8% versus 66.1%; p<0.001). The decreased incidence of ISRs with the autoinjector compared to manual injection seen in this short-term study, coupled with ease of use of the autoinjector, suggest that it could improve compliance, and therefore therapeutic outcomes in some patients.

Keywords

autoinjector compliance injection site reactions side effects

Get full access to this article

View all access options for this article.

References

Paty DW , Hartung HP , Ebers GC , Soelberg-Sorensen P , Abramsky O , Kesselring J et al. Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines . Eur J Neurol 1999; 6: S1-S35 .

Anderson DW , Ellenberg JH , Leventhal CM , Reingold SC , Rodriguez M , Silberg DH. Revised estimate of the prevalence of multiple sclerosis in the United States . Ann Neurol 1992; 31: 333-336 .

PRISMS Study Group . Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

PRISMS Study Group , University of British Columbia MS/MRI Analysis Group . PRISMS-4: long-term efficacy of interferon-b-1a in relapsing MS . Neurology 2001; 56: 1628-1636 .

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis . N Engl J Med 2000; 343: 898-904 .

Rudick R , Goodkin D , Jacobs L , Cookfair DL , Herndon RM , Richert JR et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis . Neurology 1997; 49: 358-363 .

Patti F , Reggio A. Interferon b and multiple sclerosis: look at the evidence . Int J Clin Pract 2002; Suppl 131: 23-32 .

Panitch HS , Goodin S , Francis G , Chang P , Coyle PK , O’Connor P et al. Randomized, comparative study of inter-feron beta-1a treatment regimens in MS: the EVIDENCE Trial . Neurology 2002; 59: 1496-1506 .

The IFNβ Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

10.

The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . Interferon beta- 1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .

11.

Walther E , Hohlfeld R. Multiple sclerosis. Side-effects of interferon beta therapy and their management . Neurology 1999; 53: 1622-1627 .

12.

Secondary Progressive Efficacy Trial of Recombinant Inter-feron beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon beta-1a in secondary progressive MS . Neurology 2001; 56: 1496-1504 .

13.

Lesaux J , Jadbäck G , Harragby CE. Improving the convenience of home-based interferon beta-1a therapy for multiple sclerosis . J Neurosci Nurs 1999; 21: 174-179 .

14.

Bosely EB , Capildeo R. Early use of interferon b in patients with multiple sclerosis . Int J Clin Pract 2002; Suppl 131: 17-22 .